DPY19L1

Across TCGA pan-cancer cohorts, DPY19L1 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of DPY19L1’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where DPY19L1 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types DPY19L1 is over-expressed in tumor.

CCRCC, COAD, and LUAD are the cancer types where DPY19L1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in DPY19L1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	IV	+0.745	<.001	12	view →
COAD	Male	II,III,IV	+0.309	<.001	10	view →
LUAD	Female	III,IV	+0.992	<.001	9	view →
HNSC	Male	All	+0.376	<.001	8	view →
LSCC	Male	All	+0.220	<.001	7	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

DPY19L1–CCRCC

Open the CCRCC breakdown →